These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28008661)

  • 1. Rescue alemtuzumab for refractory acute cellular rejection and bronchiolitis obliterans syndrome after lung transplantation.
    Ensor CR; Rihtarchik LC; Morrell MR; Hayanga JW; Lichvar AB; Pilewski JM; Wisniewski S; Johnson BA; D'Cunha J; Zeevi A; McDyer JF
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28008661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of aerosolized antipseudomonals on Pseudomonas positivity and bronchiolitis obliterans syndrome after lung transplantation.
    Moore CA; Pilewski JM; Venkataramanan R; Robinson KM; Morrell MR; Wisniewski SR; Zeevi A; McDyer JF; Ensor CR
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28273385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation.
    Reams BD; Musselwhite LW; Zaas DW; Steele MP; Garantziotis S; Eu PC; Snyder LD; Curl J; Lin SS; Davis RD; Palmer SM
    Am J Transplant; 2007 Dec; 7(12):2802-8. PubMed ID: 17924993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Impact of Alemtuzumab and Basiliximab Induction on Patient Survival and Time to Bronchiolitis Obliterans Syndrome in Double Lung Transplantation Recipients.
    Furuya Y; Jayarajan SN; Taghavi S; Cordova FC; Patel N; Shiose A; Leotta E; Criner GJ; Guy TS; Wheatley GH; Kaiser LR; Toyoda Y
    Am J Transplant; 2016 Aug; 16(8):2334-41. PubMed ID: 26833657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year outcomes with alemtuzumab induction after lung transplantation.
    Shyu S; Dew MA; Pilewski JM; DeVito Dabbs AJ; Zaldonis DB; Studer SM; Crespo MM; Toyoda Y; Bermudez CA; McCurry KR
    J Heart Lung Transplant; 2011 Jul; 30(7):743-54. PubMed ID: 21420318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients.
    Sacher VY; Fertel D; Srivastava K; Panos A; Nguyen D; Baxter T; Shafazand S; Pham SM
    Ann Thorac Surg; 2014 Jan; 97(1):268-74. PubMed ID: 24119986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.
    Ailawadi G; Smith PW; Oka T; Wang H; Kozower BD; Daniel TM; Kron IL; Jones DR
    J Thorac Cardiovasc Surg; 2008 Mar; 135(3):594-602. PubMed ID: 18329476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation.
    Glanville AR; Aboyoun CL; Havryk A; Plit M; Rainer S; Malouf MA
    Am J Respir Crit Care Med; 2008 May; 177(9):1033-40. PubMed ID: 18263803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bronchiolitis obliterans syndrome development in lung transplantation patients.
    Parada MT; Alba A; Sepúlveda C
    Transplant Proc; 2010; 42(1):331-2. PubMed ID: 20172344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic correlates of bronchiolitis obliterans syndrome in pulmonary retransplant recipients.
    Martinu T; Howell DN; Davis RD; Steele MP; Palmer SM
    Chest; 2006 Apr; 129(4):1016-23. PubMed ID: 16608952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-transplant baseline FEV1 and the development of bronchiolitis obliterans syndrome: an important confounder?
    Burton CM; Iversen M; Mortensen J; Carlsen J; Andersen CB; Milman N; Scheike T
    J Heart Lung Transplant; 2007 Nov; 26(11):1127-34. PubMed ID: 18022078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis.
    Kulkarni HS; Cherikh WS; Chambers DC; Garcia VC; Hachem RR; Kreisel D; Puri V; Kozower BD; Byers DE; Witt CA; Alexander-Brett J; Aguilar PR; Tague LK; Furuya Y; Patterson GA; Trulock EP; Yusen RD
    J Heart Lung Transplant; 2019 Jan; 38(1):5-16. PubMed ID: 30391193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher Risk of Acute Cellular Rejection in Lung Transplant Recipients with Cystic Fibrosis.
    Calabrese F; Lunardi F; Nannini N; Balestro E; Loy M; Marulli G; Calabrese F; Vuljan SE; Schiavon M; Perissinotto E; Rea F
    Ann Transplant; 2015 Dec; 20():769-76. PubMed ID: 26718747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adherence to home spirometry on bronchiolitis obliterans and graft survival after lung transplantation.
    Kugler C; Fuehner T; Dierich M; DeWall C; Haverich A; Simon A; Welte T; Gottlieb J
    Transplantation; 2009 Jul; 88(1):129-34. PubMed ID: 19584692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome.
    Valentine VG; Gupta MR; Walker JE; Seoane L; Bonvillain RW; Lombard GA; Weill D; Dhillon GS
    J Heart Lung Transplant; 2009 Feb; 28(2):163-9. PubMed ID: 19201342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors.
    Heng D; Sharples LD; McNeil K; Stewart S; Wreghitt T; Wallwork J
    J Heart Lung Transplant; 1998 Dec; 17(12):1255-63. PubMed ID: 9883768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of a single episode of minimal acute rejection after lung transplantation.
    Hachem RR; Khalifah AP; Chakinala MM; Yusen RD; Aloush AA; Mohanakumar T; Patterson GA; Trulock EP; Walter MJ
    Transplantation; 2005 Nov; 80(10):1406-13. PubMed ID: 16340783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation.
    Glanville AR; Aboyoun C; Klepetko W; Reichenspurner H; Treede H; Verschuuren EA; Boehler A; Benden C; Hopkins P; Corris PA;
    J Heart Lung Transplant; 2015 Jan; 34(1):16-25. PubMed ID: 25049068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The number of FoxP3+ cells in transbronchial lung allograft biopsies does not predict bronchiolitis obliterans syndrome within the first five years after transplantation.
    Krustrup D; Iversen M; Martinussen T; Schultz HH; Andersen CB
    Clin Transplant; 2015 Mar; 29(3):179-84. PubMed ID: 25533723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome.
    Daud SA; Yusen RD; Meyers BF; Chakinala MM; Walter MJ; Aloush AA; Patterson GA; Trulock EP; Hachem RR
    Am J Respir Crit Care Med; 2007 Mar; 175(5):507-13. PubMed ID: 17158279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.